Clopidogrel resistance - The cardiologist's perspective

Platelets

Volumn 18, Issue 3, 2007, Pages 175-181

  Fefer, Paul ^a,b   Hod, Hanoch ^a   Matetzky, Shlomi ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Clopidogrel resistance; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ACUTE CORONARY SYNDROME; ADVERSE OUTCOME; ANALYZER; CLINICAL TRIAL; CORONARY STENT; DRUG DOSE COMPARISON; DRUG EFFICACY; FLOW CYTOMETRY; GENETIC POLYMORPHISM; HUMAN; HYPERLIPIDEMIA; MEASUREMENT; MENTAL STRESS; PERCUTANEOUS CORONARY INTERVENTION; PHYSICAL STRESS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SMOKING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS;

BLOOD PLATELETS; CORONARY DISEASE; CORONARY THROMBOSIS; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 34248335769     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100601039747     Document Type: Review

References (50)

1. Steinhubl SR, Charnigo R, Moliterno DJ. Resistance to antiplatelet resistance is it justified? J Am Coll Cardiol 2005;45:1757-1758.
2. Bhatt DL. Aspirin resistance: More than just a laboratory curiosity. J Am Coll Cardiol 2004;43:1127-1129.
3. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-2913.
4. Wiviott SD, Antman EM. Clopidogrel resistance: A new chapter in a fast-moving story. Circulation 2004;109:3064-3067.
5. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, Bonnet JL, Alessi MC. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006;4:542-549.
6. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005;46:1820-1826.
7. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:1348-1349.
8. Matetzky S, personal communication.
9. Barragan P, Bouvier J-L, Roquebert P-O, Macaluso G, Commeau P, Comet B, Lafont A, Camoin L, Walter U, Eigenthaler M. Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Cathet Cardiovasc Intervent 2003;59:295-302.
10. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Banuelos C, Hernandez-Antolin R, Escaned J, Moreno R, Alfonso F, et al. High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability. Eur Heart J 2004;25:1903-1910.
11. Minamino T, Kitakaze M, Node K, Funaya H, Hori M. Inhibition of nitric oxide synthesis increases adenosine production via an extracellular pathway through activation of protein kinase C. Circulation 1997;96:1586-1592.
12. Lepantalo A, Virtanen KS, Heikkila J, Wartiovaara U, Lassila R. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J 2004;25:476-483.
13. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-251.
14. Muller I, Besta F, Schulz C, Li Z, Massberg S, Gawaz M. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 2003;108:2195-2197.
15. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3064-3067.
16. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Barrera Ramirez C, Sabate M, Fernandez C, Hernandez-Antolin R, Escaned J, Alfonso F, Macaya C. Platelet aggregation according to body mass index in patients undergoing coronary stenting: Should clopidogrel loading dose be weight adjusted?. J Invasive Cardiol 2004;16:169-174.
17. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, Bonnet JL, Alessi MC. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006;4:542-549.
18. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, Bray PF, Kleiman NS. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: The role of dual drug resistance. J Am Coll Cardiol 2006;47:27-33.
19. Davis JW, Hartman CR, Lewis Jr HD, Shelton L, Eigenberg DA, Hassanein KM, Hignite CE, Ruttinger HA. Cigarette smoking - induced enhancement of platelet function: Lack of prevention by aspirin in men with coronary artery disease. J Lab Clin Med 1985;105:479-483.
20. Friend M, Vucenik I, Miller M. Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ 2003;326:82-83.
21. De Gaetano G, Cerletti C. Aspirin resistance: A revival of platelet aggregation tests? J Thromb Haemost 2003;1:2048-2050.
22. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89:783-787.
23. Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, Pascal M, Herbert M, Maffrand JP, Picard C. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002;30:1288-1295.
24. Ding Z, Kim S, Dorsam RT, Jin J, Kunapuli SP. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 2003;101:3908-3914.
25. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DG, Guyer KE, Bates ER. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction. Circulation 2003;107:32-37.
26. Serebruany VL, Malinin AI, Callahan KP, Gurbel PA, Steinhubl SR. Statins do not affect platelet inhibition with clopidogrel during coronary stenting. Atherosclerosis 2001;159:239-241.
27. Muller I, Besta F, Schulz C, Li Z, Gawaz M. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 2003;108:2195-2197.
28. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004;109:1335-1338.
29. Gorchakova O, Von Beckerath N, Gawaz M, Mocz A, Joost A, Schomig A, Kastrati A. Antiplatelet effects of a 600mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 2004;25:1898-1902.
30. Serebruany VL, Midei MG, Malinin AI, Oshrine BR, Lowry DR, Sane DC, Steinhubl SR, Berger PB, O'Connor CM, Hennekens CH. Absence of interaction between atorvastatin or other statins and clopidogrel: Results from the interaction study. Arch Intern Med 2004;164:2051-2057.
31. Piorkowski M, Weikert U, Schwimmbeck PL, Martus P, Schultheiss HP, Rauch U. ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin. Thromb Haemost. 2004;92:614-620.
32. Mukherjee D, Kline-Rogers E, Fang J, Munir K, Eagle KA. Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome. Heart 2005;91:23-26.
33. Lim MJ, Spencer FA, Gore JM, Dabbous OH, Agnelli G, Kline-Rogers EM, Dibenedetto D, Eagle KA, Mehta RH; GRACE Investigators. Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: Perspectives from a large multinational registry. Eur Heart J 2005;26:1063-1069.
34. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, Guyer KE, Tait AR, Bates ER. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004;109:166-171.
35. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny J-L, Aiach M, et al. Adenosine diphosphateinduced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003;108:989-995.
36. Fontana P, Guassem P, Aiach M, Fiessinger J-N, Emmerich J, Reny J-L. P2Y12 H2 haplotype is associated with peripheral arterial disease: A case-control study. Circulation 2003;108:2971-2973.
37. Smith SMG, Judge HM, Peters G, Armstrong M, Fontana P, Guassem P, Daly ME, Storey RF. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets 2006;17:250-258.
38. Wiviott SD, Antman EM. Clopidogrel resistance: A new chapter in a fast-moving story. Circulation 2004;109:3064-3067.
39. Muller I, Seyfarth M, Rudiger S, Wolf B, Pogatsa-Murray G, Schomig A, Gawaz M. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001;85:92-93.
40. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Banuelos C, Hernandez-Antolin R, Escaned J, Moreno R, Alfonso F, et al. High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability. Eur Heart J 2004;25:1903-1910.
41. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005;45:1392-1396.
42. Von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005;112:2946-2950.
43. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005;111:2099-2106.
44. Kastrati A, Von Beckerath N, Joost A, Pogatsa-Murray G, Gorchakova O, Schomig A. Loading with 600mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 2004;110:1916-1919.
45. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, et al. JUMBO-TIMI 26 Investigators., Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005;111:3366-3373.
46. Matsumoto M. Cilostazol in secondary prevention of stroke: Impact of the Cilostazol Stroke Prevention Study. Atheroscler Suppl 2005;6:33-40.
47. Han Y, Wang S, Li Y, Jing Q, Ma Y, Deng J, Yang G, Yu H, Ge J. Cilostazol improves long-term outcomes after coronary stent implantation. Am Heart J 2005;150:568.
48. Budaj A, Yusuf S, Mehta SR, Fox KA, Tognoni G, Zhao F, Chrolavicius S, Hunt D, Keltai M, Franzosi MG. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 2002;106:1622-1626.
49. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358:527-533.
50. Steinhubl SR, Berger PB, Mann IIIrd JT, Fry ET, DeLago A, Wilmer C, Topol EJ; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288:2411-2420.